Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458507083188v1
14/3/292    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Parratt, J.
Right arrow Articles by Swingler, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parratt, J.
Right arrow Articles by Swingler, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on April 1, 2008
Multiple Sclerosis, Vol. 14, No. 3, 292-299 (2008)
DOI: 10.1177/1352458507083188
© 2008 SAGE Publications

Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis

John Parratt

Department of Neurology, University of Sydney, Blackburn Building, Camperdown, Sydney, NSW 2006, Australia, jparratt{at}bigpond.net.au

Roger Tavendale

Department of Cardiovascular Epidemiology, University of Dundee, Dundee, UK

Jonathan O'Riordan

Department of Neurology, Tayside University Hospitals, Dundee, UK

David Parratt

Department of Microbiology, Tayside University Hospitals, Dundee, UK

Robert Swingler

Department of Neurology, Tayside University Hospitals, Dundee, UK

The significance of Chlamydia pneumoniae infection in patients with multiple sclerosis (MS) is unclear. We determined the frequency of serum C. pneumoniae-specific immune complexes in patients with MS, neurological (OND) and healthy controls in a blinded, cross-sectional study. C. pneumoniae immune complexes were detected in 24% (38/156) of MS patients, 16% (11/69) of OND and 15% (77/499) of healthy controls. The odds ratio for all MS patients was 3.95 (95% CI: 2.15 to 7.24; P < 0.0001) accounting for the covariates: sex, age, socio-economic status and area of residence. The odds ratio for recently diagnosed MS patients was 4.33 (95% CI: 1.76 to 10.64; P = 0.001). Systemic C. pneumoniae infection is more frequent in MS patients than the healthy population and occurs early in the course of the disease. Multiple Sclerosis 2007; 14: 292—299. http://msj.sagepub.com

Key Words: Chlamydia pneumoniae • immune complexes • multiple sclerosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?